{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:17:48Z","timestamp":1770509868923,"version":"3.49.0"},"reference-count":124,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL076132-10"],"award-info":[{"award-number":["5T32HL076132-10"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2016.00024","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T23:11:51Z","timestamp":1469661111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants"],"prefix":"10.3389","volume":"3","author":[{"given":"Waqas","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Alirhayim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayan","family":"Qadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouaz H.","family":"Al-Mallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"issue":"2","key":"B1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1586\/14737140.4.2.303","article-title":"Venous thromboembolism and malignancy","volume":"4","author":"Gao","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"B2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/annonc\/mdp068","article-title":"Cancer and thrombosis: implications of published guidelines for clinical practice","volume":"20","author":"Khorana","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"B3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"14","key":"B4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/archinte.167.14.1471","article-title":"Venous thromboembolism in the outpatient setting","volume":"167","author":"Spencer","year":"2007","journal-title":"Arch Intern Med"},{"issue":"34","key":"B5","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"issue":"23 Suppl 1","key":"B6","doi-asserted-by":"publisher","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"B7","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"3","key":"B8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: a link between cancer and thrombosis?","volume":"5","author":"Tesselaar","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"15","key":"B9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"Elting","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"B10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1592\/phco.29.8.943","article-title":"Economic burden of venous thromboembolism in hospitalized patients","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"4","key":"B11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1751-553X.2012.01409.x","article-title":"Tissue factor expression determines tumour cell coagulation kinetics","volume":"34","author":"Welsh","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"20","key":"B12","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1021\/bi00341a041","article-title":"Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue","volume":"24","author":"Falanga","year":"1985","journal-title":"Biochemistry"},{"issue":"3","key":"B13","first-page":"795","article-title":"Tumor hypoxia, the physiological link between Trousseau\u2019s syndrome (carcinoma-induced coagulopathy) and metastasis","volume":"61","author":"Denko","year":"2001","journal-title":"Cancer Res"},{"issue":"7031","key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03357","article-title":"The MET oncogene drives a genetic programme linking cancer to haemostasis","volume":"434","author":"Boccaccio","year":"2005","journal-title":"Nature"},{"issue":"1","key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-2002-20564","article-title":"Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans","volume":"28","author":"Varki","year":"2002","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"B16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1172\/JCI200318882","article-title":"Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas","volume":"112","author":"Wahrenbrock","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","article-title":"Incidence of venous thromboembolism in patients hospitalized with cancer","volume":"119","author":"Stein","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"B18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"10","key":"B19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/S0959-8049(97)00167-6","article-title":"Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study","volume":"33","author":"Brandes","year":"1997","journal-title":"Eur J Cancer"},{"issue":"4","key":"B20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J Neurosurg"},{"issue":"10","key":"B21","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"Khorana","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"B22","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/annonc\/mdm284","article-title":"Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients","volume":"18","author":"Mandal\u00e0","year":"2007","journal-title":"Ann Oncol"},{"issue":"10","key":"B23","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/cncr.22626","article-title":"The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma","volume":"109","author":"Tetzlaff","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"B24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/jso.1158","article-title":"Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer","volume":"78","author":"Franchi","year":"2001","journal-title":"J Surg Oncol"},{"issue":"7","key":"B25","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjc.6604658","article-title":"Silent venous thromboembolism before treatment in endometrial cancer and the risk factors","volume":"99","author":"Satoh","year":"2008","journal-title":"Br J Cancer"},{"issue":"5","key":"B26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cncr.20893","article-title":"Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine","volume":"103","author":"Numico","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"B27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/JTO.0b013e31811ea275","article-title":"High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients","volume":"2","author":"Tagalakis","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"6","key":"B28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"10","key":"B29","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1538-7836.2004.00928.x","article-title":"The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma","volume":"2","author":"Blom","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"4","key":"B30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"Sallah","year":"2002","journal-title":"Thromb Haemost"},{"issue":"3","key":"B31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","article-title":"Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study","volume":"4","author":"Blom","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"B32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"B33","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"B34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","article-title":"Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival","volume":"4","author":"Zangari","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"1","key":"B36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"issue":"16","key":"B37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"B38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"B39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2008.09.005","article-title":"Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the \u2018GISCAD-alternating schedule\u2019 study findings","volume":"45","author":"Mandal\u00e0","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"B40","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"B41","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","article-title":"Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer","volume":"168","author":"Khorana","year":"2008","journal-title":"Arch Intern Med"},{"issue":"9610","key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(08)60202-0","article-title":"Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study","volume":"371","author":"Cohen","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"B43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2005.04.2150","article-title":"Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival","volume":"24","author":"Alcalay","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"B44","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ygyno.2007.02.024","article-title":"Venous thromboembolism in ovarian cancer","volume":"105","author":"Rodriguez","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"B45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann Surg"},{"issue":"19","key":"B46","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"B47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.6004\/jnccn.2006.0074","article-title":"Catheter-related thrombosis: risks, diagnosis, and management","volume":"4","author":"Linenberger","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"B48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kr\u00f6ger","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"B49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"B50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.mbc.0000224845.27378.c3","article-title":"Risk factors associated with venous thromboembolic events in patients with malignancy","volume":"17","author":"Lin","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"B51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2007.05.028","article-title":"Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy","volume":"53","author":"Secin","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"B52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"B53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.thromres.2007.10.009","article-title":"Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma","volume":"122","author":"Connolly","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"B54","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/10428190600560991","article-title":"Venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"47","author":"Komrokji","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"6 Pt 1","key":"B55","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1097\/00005392-199812010-00022","article-title":"High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy","volume":"160","author":"Czaykowski","year":"1998","journal-title":"J Urol"},{"issue":"4","key":"B56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1538-7836.2008.02908.x","article-title":"The incidence of venous thromboembolism among patients with primary lung cancer","volume":"6","author":"Chew","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"10","key":"B57","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1996.14.10.2731","article-title":"Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group","volume":"14","author":"Pritchard","year":"1996","journal-title":"J Clin Oncol"},{"issue":"25","key":"B58","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"B59","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"B60","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","article-title":"Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416","volume":"21","author":"Kuenen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"B61","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"B62","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"3","key":"B63","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2141.2004.05327.x","article-title":"Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients","volume":"128","author":"Kennedy","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"B64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"9","key":"B65","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"11","key":"B66","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"Khorana","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"6","key":"B67","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1538-7836.2005.01346.x","article-title":"Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis","volume":"3","author":"Eroglu","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"18","key":"B68","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1200\/JCO.2005.10.192","article-title":"Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer","volume":"23","author":"Couban","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"B69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"18","key":"B70","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1200\/JCO.2005.06.084","article-title":"Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients","volume":"23","author":"Verso","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"B71","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/S0049-3848(12)70027-0","article-title":"New and old anticoagulants in cancer","volume":"129","author":"Verso","year":"2012","journal-title":"Thromb Res"},{"issue":"6 Suppl","key":"B72","doi-asserted-by":"publisher","first-page":"381s","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"issue":"3","key":"B73","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.critrevonc.2006.05.001","article-title":"Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)","volume":"59","author":"Mandal\u00e0","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 5","key":"B74","doi-asserted-by":"publisher","first-page":"v274","DOI":"10.1093\/annonc\/mdq199","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management","volume":"21","author":"Mandala","year":"2010","journal-title":"Ann Oncol"},{"issue":"13","key":"B75","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"B76","doi-asserted-by":"publisher","first-page":"Cd004318","DOI":"10.1002\/14651858.CD004318.pub2","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","author":"Rasmussen","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9679","key":"B77","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/S0140-6736(09)60941-7","article-title":"Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial","volume":"373","author":"Dennis","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 2","key":"B78","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/S0049-3848(10)70027-X","article-title":"Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients","volume":"125","author":"Farge","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"B79","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/annonc\/mdj059","article-title":"Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial","volume":"17","author":"Karthaus","year":"2006","journal-title":"Ann Oncol"},{"issue":"8902","key":"B80","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"B81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"B82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"29","key":"B83","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"B84","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"issue":"4","key":"B85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"B86","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"B87","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"B88","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"8","key":"B89","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/j.1538-7836.2007.02613.x","article-title":"A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)","volume":"5","author":"Kovacs","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9","key":"B90","doi-asserted-by":"crossref","first-page":"838","DOI":"10.6004\/jnccn.2006.0071","article-title":"Venous thromboembolic disease. Clinical practice guidelines in oncology","volume":"4","author":"Wagman","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"B91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1538-7836.2007.02468.x","article-title":"Is it worth diagnosing and treating distal deep vein thrombosis? No","volume":"5","author":"Righini","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"B92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1538-7836.2007.02490.x","article-title":"Worth diagnosing? Yes","volume":"5","author":"Schellong","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"B93","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1160\/TH09-01-0053","article-title":"Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study","volume":"102","author":"Galanaud","year":"2009","journal-title":"Thromb Haemost"},{"issue":"8454","key":"B94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(85)90459-3","article-title":"Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis","volume":"2","author":"Lagerstedt","year":"1985","journal-title":"Lancet"},{"issue":"Suppl 2","key":"B95","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/S0049-3848(10)70030-X","article-title":"The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients","volume":"125","author":"Streiff","year":"2010","journal-title":"Thromb Res"},{"issue":"8","key":"B96","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1538-7836.2009.03464.x","article-title":"Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency","volume":"7","author":"Enden","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"4","key":"B97","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2214\/AJR.09.3214","article-title":"Deep venous thrombosis: the opportunity at hand","volume":"193","author":"Vedantham","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"B98","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s00520-012-1413-z","article-title":"Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial","volume":"20","author":"Barginear","year":"2012","journal-title":"Support Care Cancer"},{"issue":"7","key":"B99","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM199802123380701","article-title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave Study Group","volume":"338","author":"Decousus","year":"1998","journal-title":"N Engl J Med"},{"issue":"13","key":"B100","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1001\/archinte.160.13.2033","article-title":"A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism","volume":"160","author":"White","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"B101","doi-asserted-by":"crossref","first-page":"881","DOI":"10.6004\/jnccn.2006.0073","article-title":"Inferior vena cava filters in the cancer patient: current use and indications","volume":"4","author":"Getzen","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"B102","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1001\/archinternmed.2010.316","article-title":"Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade","volume":"170","author":"Nicholson","year":"2010","journal-title":"Arch Intern Med"},{"issue":"15","key":"B103","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa021274","article-title":"Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism","volume":"347","author":"Konstantinides","year":"2002","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/asheducation-2010.1.144","article-title":"Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants","volume":"2010","author":"Lee","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"B105","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1016\/S0049-3848(12)70035-X","article-title":"Treatment of established thrombotic events in patients with cancer","volume":"129","author":"Lee","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"B106","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.3747\/co.2008.177","article-title":"Cancer-associated thrombosis: prevention and treatment","volume":"15","author":"Brose","year":"2008","journal-title":"Curr Oncol"},{"issue":"5","key":"B107","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9","key":"B108","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"6","key":"B109","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1538-7836.2010.03892.x","article-title":"Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study","volume":"8","author":"Kakkar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"B110","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1538-7836.2009.03301.x","article-title":"AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery \u2013 TREK: a dose-ranging study","volume":"7","author":"Lassen","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"16","key":"B111","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"issue":"5","key":"B112","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"J Bone Joint Surg Br"},{"issue":"26","key":"B113","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"issue":"9676","key":"B114","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"B115","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"issue":"12","key":"B116","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9717","key":"B117","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"B118","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"B119","first-page":"21","article-title":"Rivaroxaban vs. enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: Magellan subgroup analyses","volume":"9","author":"Cohen","year":"2011","journal-title":"J Thromb Haemostasis"},{"issue":"5","key":"B120","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"B121","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"2","key":"B122","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11239-014-1102-5","article-title":"Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism","volume":"39","author":"Mantha","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"20","key":"B123","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMc1303641","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"B124","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T16:39:24Z","timestamp":1568219964000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fcvm.2016.00024\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":124,"URL":"https:\/\/doi.org\/10.3389\/fcvm.2016.00024","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}